المؤلفون: Brown GC; Department of Pharmacoeconomics, Center for Value-Based Medicine, Hilton Head, South Carolina; Wills Eye Hospital, Philadelphia, Pennsylvania; Sidney Kimmel School of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania; Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia. Electronic address: gbrown@valuebasedmedicine.com., Brown MM; Department of Pharmacoeconomics, Center for Value-Based Medicine, Hilton Head, South Carolina; Wills Eye Hospital, Philadelphia, Pennsylvania; Sidney Kimmel School of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania; Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia., Monigle MC; Beverly Hospital, Beth Israel Lahey Health, Beverly, Massachusetts.

المصدر: Ophthalmology. Retina [Ophthalmol Retina] 2024 May; Vol. 8 (5), pp. 431-446. Date of Electronic Publication: 2023 Nov 21.

نوع المنشور: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Published by Elsevier Inc. on behalf of American Academy of Ophthalmology Country of Publication: United States NLM ID: 101695048 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2468-6530 (Electronic) Linking ISSN: 24686530 NLM ISO Abbreviation: Ophthalmol Retina Subsets: MEDLINE

مواضيع طبية MeSH: Angiogenesis Inhibitors*/administration & dosage , Angiogenesis Inhibitors*/economics , Cost-Benefit Analysis* , Intravitreal Injections* , Ranibizumab*/administration & dosage , Ranibizumab*/economics , Visual Acuity* , Wet Macular Degeneration*/drug therapy , Wet Macular Degeneration*/economics , Wet Macular Degeneration*/diagnosis, Aged ; Female ; Humans ; Male ; Drug Delivery Systems/economics ; Follow-Up Studies ; Quality of Life ; Quality-Adjusted Life Years ; Tomography, Optical Coherence ; Treatment Outcome ; Vascular Endothelial Growth Factor A/antagonists & inhibitors

المؤلفون: Honda Y; Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, 54 Shogoin-kawahara-cho, Sakyo-ku, Kyoto City, Kyoto Prefecture, 606-8507, Japan., Miyata M; Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, 54 Shogoin-kawahara-cho, Sakyo-ku, Kyoto City, Kyoto Prefecture, 606-8507, Japan. miyatam@kuhp.kyoto-u.ac.jp., Miyake M; Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, 54 Shogoin-kawahara-cho, Sakyo-ku, Kyoto City, Kyoto Prefecture, 606-8507, Japan., Hata M; Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, 54 Shogoin-kawahara-cho, Sakyo-ku, Kyoto City, Kyoto Prefecture, 606-8507, Japan., Numa S; Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, 54 Shogoin-kawahara-cho, Sakyo-ku, Kyoto City, Kyoto Prefecture, 606-8507, Japan., Mori Y; Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, 54 Shogoin-kawahara-cho, Sakyo-ku, Kyoto City, Kyoto Prefecture, 606-8507, Japan., Ooto S; Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, 54 Shogoin-kawahara-cho, Sakyo-ku, Kyoto City, Kyoto Prefecture, 606-8507, Japan., Tamura H; Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, 54 Shogoin-kawahara-cho, Sakyo-ku, Kyoto City, Kyoto Prefecture, 606-8507, Japan., Ueda-Arakawa N; Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, 54 Shogoin-kawahara-cho, Sakyo-ku, Kyoto City, Kyoto Prefecture, 606-8507, Japan., Muraoka Y; Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, 54 Shogoin-kawahara-cho, Sakyo-ku, Kyoto City, Kyoto Prefecture, 606-8507, Japan., Takahashi A; Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, 54 Shogoin-kawahara-cho, Sakyo-ku, Kyoto City, Kyoto Prefecture, 606-8507, Japan., Sado K; Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, 54 Shogoin-kawahara-cho, Sakyo-ku, Kyoto City, Kyoto Prefecture, 606-8507, Japan., Kido A; Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, 54 Shogoin-kawahara-cho, Sakyo-ku, Kyoto City, Kyoto Prefecture, 606-8507, Japan., Tsujikawa A; Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, 54 Shogoin-kawahara-cho, Sakyo-ku, Kyoto City, Kyoto Prefecture, 606-8507, Japan.

المصدر: Scientific reports [Sci Rep] 2024 Jun 11; Vol. 14 (1), pp. 13399. Date of Electronic Publication: 2024 Jun 11.

نوع المنشور: Journal Article; Observational Study

بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

مواضيع طبية MeSH: Ranibizumab*/administration & dosage , Ranibizumab*/therapeutic use , Recombinant Fusion Proteins*/administration & dosage , Recombinant Fusion Proteins*/therapeutic use , Receptors, Vascular Endothelial Growth Factor*/administration & dosage , Receptors, Vascular Endothelial Growth Factor*/therapeutic use , Vascular Endothelial Growth Factor A*/antagonists & inhibitors , Myopia, Degenerative*/drug therapy , Myopia, Degenerative*/complications , Visual Acuity* , Angiogenesis Inhibitors*/therapeutic use , Angiogenesis Inhibitors*/administration & dosage, Humans ; Male ; Female ; Aged ; Retrospective Studies ; Treatment Outcome ; Middle Aged ; Intravitreal Injections ; Choroidal Neovascularization/drug therapy ; Choroidal Neovascularization/pathology ; Retinal Neovascularization/drug therapy ; Retinal Neovascularization/pathology

المؤلفون: Nam KT; Department of Ophthalmology, Jeju National University College of Medicine, Jeju, Korea., Yun C; Department of Ophthalmology, Korea University College of Medicine, Seoul, Korea., Lee YJ; Department of Ophthalmology, Korea University College of Medicine, Seoul, Korea., Choi M; Department of Ophthalmology, Korea University College of Medicine, Seoul, Korea., Kang D; Clear Eye Clinic, Gyeonggi-do, Korea., Oh J; Department of Ophthalmology, Korea University College of Medicine, Seoul, Korea.

المصدر: Current eye research [Curr Eye Res] 2024 Jun; Vol. 49 (6), pp. 663-670. Date of Electronic Publication: 2024 Mar 07.

نوع المنشور: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Informa Healthcare Country of Publication: England NLM ID: 8104312 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1460-2202 (Electronic) Linking ISSN: 02713683 NLM ISO Abbreviation: Curr Eye Res Subsets: MEDLINE

مواضيع طبية MeSH: Ranibizumab*/administration & dosage , Ranibizumab*/therapeutic use , Visual Acuity*/physiology , Angiogenesis Inhibitors*/therapeutic use , Angiogenesis Inhibitors*/administration & dosage , Intravitreal Injections* , Tomography, Optical Coherence* , Fluorescein Angiography* , Biosimilar Pharmaceuticals*/therapeutic use , Vascular Endothelial Growth Factor A*/antagonists & inhibitors, Humans ; Male ; Female ; Aged ; Polyps/drug therapy ; Polyps/diagnosis ; Polyps/physiopathology ; Treatment Outcome ; Choroid/blood supply ; Choroid/pathology ; Middle Aged ; Subretinal Fluid ; Follow-Up Studies ; Fundus Oculi ; Double-Blind Method ; Polypoidal Choroidal Vasculopathy

المؤلفون: Chen H; Department of Ophthalmology, the Sixth Hospital of Beijing, Beijing, China., Shi X; Beijing Tongren Hospital, Capital Medical University, Beijing, China., Zhang W; Department of Ophthalmology, the Sixth Hospital of Beijing, Beijing, China., Han Q; Department of Ophthalmology, the Sixth Hospital of Beijing, Beijing, China.

المصدر: European journal of ophthalmology [Eur J Ophthalmol] 2024 May; Vol. 34 (3), pp. 615-623. Date of Electronic Publication: 2023 May 24.

نوع المنشور: Journal Article; Meta-Analysis; Comparative Study; Review

بيانات الدورية: Publisher: SAGE Publishing Country of Publication: United States NLM ID: 9110772 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1724-6016 (Electronic) Linking ISSN: 11206721 NLM ISO Abbreviation: Eur J Ophthalmol Subsets: MEDLINE

مواضيع طبية MeSH: Macular Edema*/drug therapy , Macular Edema*/diagnosis , Macular Edema*/physiopathology , Ranibizumab*/administration & dosage , Ranibizumab*/therapeutic use , Diabetic Retinopathy*/drug therapy , Diabetic Retinopathy*/diagnosis , Diabetic Retinopathy*/physiopathology , Recombinant Fusion Proteins*/administration & dosage , Recombinant Fusion Proteins*/therapeutic use , Receptors, Vascular Endothelial Growth Factor*/administration & dosage , Receptors, Vascular Endothelial Growth Factor*/therapeutic use , Intravitreal Injections* , Visual Acuity*/physiology , Angiogenesis Inhibitors*/administration & dosage , Angiogenesis Inhibitors*/therapeutic use , Vascular Endothelial Growth Factor A*/antagonists & inhibitors, Humans ; Randomized Controlled Trials as Topic ; Tomography, Optical Coherence ; Treatment Outcome

المؤلفون: Morotti F; Neonatal Intensive Care Unit, Children's Hospital, ASST Spedali Civili di Brescia, Brescia, Italy., Aversa S; Neonatal Intensive Care Unit, Children's Hospital, ASST Spedali Civili di Brescia, Brescia, Italy aversalvo@gmail.com., Barbieri F; Neonatal Intensive Care Unit, Children's Hospital, ASST Spedali Civili di Brescia, Brescia, Italy., Risso FM; Neonatal Intensive Care Unit, Children's Hospital, ASST Spedali Civili di Brescia, Brescia, Italy.

المصدر: BMJ case reports [BMJ Case Rep] 2024 Jun 05; Vol. 17 (6). Date of Electronic Publication: 2024 Jun 05.

نوع المنشور: Journal Article; Case Reports

بيانات الدورية: Publisher: BMJ Pub. Group Country of Publication: England NLM ID: 101526291 Publication Model: Electronic Cited Medium: Internet ISSN: 1757-790X (Electronic) Linking ISSN: 1757790X NLM ISO Abbreviation: BMJ Case Rep Subsets: MEDLINE

مواضيع طبية MeSH: Retinopathy of Prematurity*/drug therapy , Enterocolitis, Necrotizing*/drug therapy , Ranibizumab*/administration & dosage , Ranibizumab*/therapeutic use , Intravitreal Injections* , Angiogenesis Inhibitors*/administration & dosage , Angiogenesis Inhibitors*/adverse effects, Humans ; Infant, Newborn ; Male ; Infant, Premature ; Female ; Vascular Endothelial Growth Factor A/antagonists & inhibitors

المؤلفون: Giannos SA; Department of Ophthalmology and Visual Sciences, University of Texas Medical Branch, Galveston, TX, USA. stevena.giannos@viatris.com., Kraft ER; Department of Ophthalmology and Visual Sciences, University of Texas Medical Branch, Galveston, TX, USA., Luisi JD; Department of Ophthalmology and Visual Sciences, University of Texas Medical Branch, Galveston, TX, USA., Schmitz-Brown ME; Department of Ophthalmology and Visual Sciences, University of Texas Medical Branch, Galveston, TX, USA., Reffatto V; Department of Ophthalmology and Visual Sciences, University of Texas Medical Branch, Galveston, TX, USA., Merkley KH; Department of Ophthalmology and Visual Sciences, University of Texas Medical Branch, Galveston, TX, USA., Gupta PK; Department of Ophthalmology and Visual Sciences, University of Texas Medical Branch, Galveston, TX, USA. prgupta@utmb.edu.

المصدر: Pharmaceutical research [Pharm Res] 2024 Jun; Vol. 41 (6), pp. 1247-1256. Date of Electronic Publication: 2024 Jun 05.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Kluwer Academic/Plenum Publishers Country of Publication: United States NLM ID: 8406521 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-904X (Electronic) Linking ISSN: 07248741 NLM ISO Abbreviation: Pharm Res Subsets: MEDLINE

مواضيع طبية MeSH: Ranibizumab*/administration & dosage , Ranibizumab*/pharmacokinetics , Bevacizumab*/administration & dosage , Bevacizumab*/pharmacokinetics , Ophthalmic Solutions*/administration & dosage , Retina*/metabolism , Retina*/drug effects, Animals ; Rabbits ; Angiogenesis Inhibitors/administration & dosage ; Angiogenesis Inhibitors/pharmacokinetics ; Vitreous Body/metabolism ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Intravitreal Injections ; Biosimilar Pharmaceuticals/administration & dosage ; Biosimilar Pharmaceuticals/pharmacokinetics ; Wet Macular Degeneration/drug therapy

المؤلفون: Payne CJ; Case Western Reserve University School of Medicine, Cleveland, OH, USA., Gupta U; Case Western Reserve University School of Medicine, Cleveland, OH, USA., Maatouk CM; Case Western Reserve University School of Medicine, Cleveland, OH, USA.; Cleveland Clinic Cole Eye Institute Center for Ophthalmic Bioinformatics, Cleveland, OH, USA., Kuo BL; Case Western Reserve University School of Medicine, Cleveland, OH, USA.; Cleveland Clinic Cole Eye Institute Center for Ophthalmic Bioinformatics, Cleveland, OH, USA., Perkins SW; Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA., Singh RP; Cleveland Clinic Cole Eye Institute Center for Ophthalmic Bioinformatics, Cleveland, OH, USA.; Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA., Talcott KE; Cleveland Clinic Cole Eye Institute Center for Ophthalmic Bioinformatics, Cleveland, OH, USA. talcotk@ccf.org.

المصدر: Eye (London, England) [Eye (Lond)] 2024 Jun; Vol. 38 (9), pp. 1687-1693. Date of Electronic Publication: 2024 Mar 06.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8703986 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5454 (Electronic) Linking ISSN: 0950222X NLM ISO Abbreviation: Eye (Lond) Subsets: MEDLINE

مواضيع طبية MeSH: Macular Edema*/drug therapy , Macular Edema*/physiopathology , Macular Edema*/etiology , Diabetic Retinopathy*/drug therapy , Diabetic Retinopathy*/physiopathology , Visual Acuity*/physiology , Angiogenesis Inhibitors*/administration & dosage , Angiogenesis Inhibitors*/therapeutic use , Intravitreal Injections* , Vascular Endothelial Growth Factor A*/antagonists & inhibitors , Ranibizumab*/administration & dosage , Ranibizumab*/therapeutic use , Bevacizumab*/administration & dosage , Bevacizumab*/therapeutic use, Humans ; Male ; Retrospective Studies ; Female ; Middle Aged ; Aged ; Tomography, Optical Coherence ; Drug Administration Schedule ; Treatment Outcome ; Receptors, Vascular Endothelial Growth Factor/administration & dosage ; Receptors, Vascular Endothelial Growth Factor/therapeutic use

المؤلفون: Sepah YJ; Byers Eye Institute, Spencer Center for Vision Research, Stanford University, Palo Alto, CA, USA., Do DV; Byers Eye Institute, Spencer Center for Vision Research, Stanford University, Palo Alto, CA, USA., Mesquida M; Roche Pharma Research and Early Development, Basel, Switzerland., Day BM; Genentech Inc., South San Francisco, CA, USA., Blotner S; Genentech Inc., South San Francisco, CA, USA., Afridi R; Byers Eye Institute, Spencer Center for Vision Research, Stanford University, Palo Alto, CA, USA.; Ocular Imaging Research and Reading Center, Sunnyvale, CA, USA., Halim MS; Byers Eye Institute, Spencer Center for Vision Research, Stanford University, Palo Alto, CA, USA.; Ocular Imaging Research and Reading Center, Sunnyvale, CA, USA., Hong K; Genentech Inc., South San Francisco, CA, USA., Wakshull E; Genentech Inc., South San Francisco, CA, USA., Fauser S; Roche Pharma Research and Early Development, Basel, Switzerland., Stoilov I; Genentech Inc., South San Francisco, CA, USA. stoilovi@gene.com., Dong Nguyen Q; Byers Eye Institute, Spencer Center for Vision Research, Stanford University, Palo Alto, CA, USA. ndquan@stanford.edu.

مؤلفون مشاركون: HARBOR, READ-3 Investigators

المصدر: Eye (London, England) [Eye (Lond)] 2024 Jun; Vol. 38 (9), pp. 1755-1761. Date of Electronic Publication: 2024 Apr 15.

نوع المنشور: Journal Article; Multicenter Study; Randomized Controlled Trial

بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8703986 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5454 (Electronic) Linking ISSN: 0950222X NLM ISO Abbreviation: Eye (Lond) Subsets: MEDLINE

مواضيع طبية MeSH: Ranibizumab*/administration & dosage , Ranibizumab*/therapeutic use , Interleukin-6*/metabolism , Visual Acuity*/physiology , Aqueous Humor*/metabolism , Angiogenesis Inhibitors*/therapeutic use , Angiogenesis Inhibitors*/administration & dosage , Intravitreal Injections* , Vascular Endothelial Growth Factor A*/antagonists & inhibitors , Vascular Endothelial Growth Factor A*/metabolism , Macular Edema*/drug therapy , Macular Edema*/metabolism , Diabetic Retinopathy*/drug therapy , Diabetic Retinopathy*/metabolism , Diabetic Retinopathy*/physiopathology, Humans ; Male ; Female ; Double-Blind Method ; Aged ; Middle Aged ; Wet Macular Degeneration/drug therapy ; Wet Macular Degeneration/metabolism ; Wet Macular Degeneration/physiopathology ; Aged, 80 and over

المؤلفون: Jhaveri A; From the Temerty Faculty of Medicine (A.J., M.B., A.M.), University of Toronto, Toronto, Ontario, Canada., Balas M; From the Temerty Faculty of Medicine (A.J., M.B., A.M.), University of Toronto, Toronto, Ontario, Canada., Khalid F; Michael DeGroote School of Medicine (F.K.), McMaster University, Hamilton, Ontario, Canada., Mihalache A; From the Temerty Faculty of Medicine (A.J., M.B., A.M.), University of Toronto, Toronto, Ontario, Canada., Popovic MM; Department of Ophthalmology and Vision Sciences (M.M.P., P.J.K., R.H.M.), University of Toronto, Toronto, Ontario, Canada., Kertes PJ; Department of Ophthalmology and Vision Sciences (M.M.P., P.J.K., R.H.M.), University of Toronto, Toronto, Ontario, Canada; John and Liz Tory Eye Centre (P.J.K.), Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada., Muni RH; Department of Ophthalmology and Vision Sciences (M.M.P., P.J.K., R.H.M.), University of Toronto, Toronto, Ontario, Canada; Department of Ophthalmology (R.H.M.), St. Michael's Hospital/Unity Health Toronto, Toronto, Ontario, Canada. Electronic address: rajeev.muni@utoronto.ca.

المصدر: American journal of ophthalmology [Am J Ophthalmol] 2024 Jun; Vol. 262, pp. 86-96. Date of Electronic Publication: 2024 Jan 18.

نوع المنشور: Meta-Analysis; Journal Article; Systematic Review; Review

بيانات الدورية: Publisher: Elsevier Science Country of Publication: United States NLM ID: 0370500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-1891 (Electronic) Linking ISSN: 00029394 NLM ISO Abbreviation: Am J Ophthalmol Subsets: MEDLINE

مواضيع طبية MeSH: Angiogenesis Inhibitors*/adverse effects , Angiogenesis Inhibitors*/administration & dosage , Vascular Endothelial Growth Factor A*/antagonists & inhibitors , Intravitreal Injections* , Recombinant Fusion Proteins*/adverse effects , Recombinant Fusion Proteins*/administration & dosage , Receptors, Vascular Endothelial Growth Factor*/antagonists & inhibitors , Receptors, Vascular Endothelial Growth Factor*/administration & dosage , Ranibizumab*/adverse effects , Ranibizumab*/administration & dosage, Humans ; Bevacizumab/adverse effects ; Bevacizumab/administration & dosage ; Randomized Controlled Trials as Topic ; Venous Thrombosis ; Thrombosis/chemically induced ; Thrombosis/prevention & control

المؤلفون: Sepetis AE; Department of Ophthalmology, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, SO16 6YD, Hampshire, United Kingdom., Barbara R; Department of Ophthalmology, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, SO16 6YD, Hampshire, United Kingdom., Frisina R; Ophthalmology - Surgery Department, Guglielmo da Saliceto Hospital, Piacenza, Italy., Farag M; Department of Ophthalmology, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, SO16 6YD, Hampshire, United Kingdom., De Salvo G; Department of Ophthalmology, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, SO16 6YD, Hampshire, United Kingdom. gabrielladesalvo@gmail.com.

المصدر: Eye (London, England) [Eye (Lond)] 2024 Jun; Vol. 38 (8), pp. 1438-1443. Date of Electronic Publication: 2024 Jan 06.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8703986 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5454 (Electronic) Linking ISSN: 0950222X NLM ISO Abbreviation: Eye (Lond) Subsets: MEDLINE

مواضيع طبية MeSH: Angiogenesis Inhibitors*/therapeutic use , Intravitreal Injections* , Ranibizumab*/therapeutic use , Ranibizumab*/administration & dosage , Tomography, Optical Coherence* , Vascular Endothelial Growth Factor A*/antagonists & inhibitors , Visual Acuity*/physiology, Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Bevacizumab/therapeutic use ; Fluorescein Angiography ; Follow-Up Studies ; Macula Lutea/pathology ; Macula Lutea/diagnostic imaging ; Retrospective Studies ; Treatment Outcome ; Wet Macular Degeneration/drug therapy ; Wet Macular Degeneration/physiopathology ; Wet Macular Degeneration/diagnosis